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Outline 
• Network pharmacology 
 
• Case study I :   Pre-Clinical Drug Prioritization 
via Prognosis-Guided Genetic Interaction 
Networks 
 
• Case study II :  Dynamic remodeling of  
context-specific miRNAs regulation networks 
facilitate in silico cancer drug screening 
 
• What’s next 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.6
45
5.
1 
: P
os
te
d 
24
 S
ep
 2
01
1
Network – a better knowledge 
representation 
     Linear pathway               network Nat
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Network pharmacology 
Network Pharmacology attempts 
to model the effects of a drug 
action by simultaneously 
modulating multiple proteins in 
a network 
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Case Study I 
 
Pre-Clinical Drug Prioritization via 
Prognosis-Guided Genetic Interaction 
Networks 
 
Jianghui Xiong et al. PLoS ONE. 2010 
 
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0013937 
(Full text download) 
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Oncology Drug Development 
One of most challenging scientific problems 
What’s wrong with our cancer models? NATURE REVIEWS DRUG DISCOVERY,  2005 
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The current models used for pre-clinical drug testing Do NOT 
accurately predict how new treatments will act in clinical trials 
– Heterogeneity in patient populations 
– Unpredictable physiology 
 
What’s wrong with our cancer models? NATURE REVIEWS DRUG DISCOVERY,  2005 
What’s wrong with our Disease Models 
Drug Discov Today Dis Models, 2008 
? 
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Hypothesis 
– The difficulty of identifying effective cancer cures (as 
evidenced by drug resistance) may be a consequence of 
the robustness of physiology-level (or 
microenvironment-level) network regulation 
– Network (robustness) as drug target 
• Gene networks associated with cancer outcome in 
heterogeneous patient populations 
 
Pre-clinical in silico Cancer Models for Drug 
Prioritization 
– Incorporating heterogeneity and in vivo physiology 
information, which MISSING in pre-clinical cancer models 
 
 
Our proposal 
1 
2 
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What type of gene network? 
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Synthetic lethal provide 
approach for drug combination  
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Synthetic lethal provide approach for 
improving targeted therapies (drug 
combination) 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.6
45
5.
1 
: P
os
te
d 
24
 S
ep
 2
01
1
Synthetic lethal provide approach for 
personalized therapy 
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What type of gene network? 
– We proposed a novel in vivo genetic 
interaction between genes as ‘synergistic 
outcome determination’ (SOD), in a similar 
way to ‘synthetic lethality’ 
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SOD (Synergistic Outcome Determination) 
-- not Superoxide dismutase  Bad Outcome 
Gene Pair 
Gene 
A 
Gene 
B 
Bad Outcome 
Gene Pair 
Gene 
A 
Gene 
B 
Good Outcome 
Gene Pair 
Gene 
A 
Gene 
B 
Good Outcome 
Gene Pair 
Gene 
A 
Gene 
B 
Synergistically Infered Nexus ( SIN ) 
 
 
 
𝑆𝑦𝑛 𝐺1, 𝐺2; 𝐶 = 𝐼 𝐺1, 𝐺2; 𝐶  −   𝐼 𝐺1; 𝐶 +  𝐼(𝐺2; 𝐶)  
𝐼 𝑋; 𝑌 =   𝑝 𝑥, 𝑦 log2
𝑝(𝑥, 𝑦)
𝑝 𝑥 𝑝(𝑦)
𝑦𝑥
 
SOD is defined as the 
synergy of a gene pair 
with respect to cancer 
patients’ outcome, 
whose correlation with 
outcome is due to 
cooperative, rather than 
independent, 
contributions of genes.  
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SOD (Synergistic Outcome Determination)  
vs Synthetic Lethality 
Feature 
compared 
 
SOD 
 
Synthetic 
Lethality 
Phenotype Survival outcome of 
individual patient 
Cell 
death/growth 
Systems 
Level 
human body Cell 
Data 
Accessible  
Human population 
(via computation) 
Yeast (SGA); 
Human cell lines; 
Human 
population 
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The pipeline 
Protein Network 
Pathway 
Gene Ontology 
miRNA Target Gene 
Gene Module 
Database 
Prognostic Data 
Inter-Module 
Cooperation 
Network 
1 
Compound in vitro 
screen data 
NCI 60 panel gene 
Expression data 
Gene Signature for 
Compound Sensitivity 
Compound route of action 
Analysis 
Perturbation Index (PI) 
Benchmarking/Validation 
Drug Combination 
Simulation 
2 
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What is Gene Module?  
And Why We use it instead of the single genes? 
Gene Module:  
a group of genes which  
share similar function 
a 
b 
c 
d 
e f 
Gene Module 1 
x A single gene 
…… 
Gene Module 2 
Gene Module 3 
Gene Module 4 
Gene Module n 
…… 
Gene Module: 
robust/reproducible features rather than single genes 
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Gene Module Database 
Protein 
Network 
Pathway 
Gene  
Ontology 
miRNA  
Target 
Gene 
Gene Module 
Database 
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Chang H Y et al. PNAS 2005;102:3738-3743 
a “wound response” gene 
expression signature in predicting 
breast cancer progression 
• Natural population  
        -  Heterogeneity 
• Tumor tissue  
        -  Microenvironment reflection 
• Final point phenotype  
        -  Survival time 
• Comprehensive genomic 
characterization 
• Large Data Set  
 
Prognosis Data 
 -- data associated gene expression with 
patients’ phenotype (prognosis)  
Benefit of Prognosis Data   Prognosis Data Instance   
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Gene Module 
Database 
Module-module cooperation network 
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SIN analysis 
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Inter-Module Cooperation Network  (IMCN)  
for lung cancer suggests that the network robustness highly 
dependent on gatekeeper modules 
 
Gatekeeper 
Module 
Checkpoint 
Module 
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The biological themes of the most highly connected 
gatekeeper modules in multiple types of cancer 
‘Gatekeeper’ modules for lung cancer (NSCLC) 
3 Major 
Biological  
Theme  
These common themes indicate the pivotal role of the in vivo tumor 
microenvironment, and the efficacy of drugs could be regulated by these components  
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Contribution of various evidence sources  
for gene module definition 
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Association of gatekeeper modules with 
genetic and epigenetic aberration events 
 
• Comparing genetic (somatic mutation) and epigenetic (DNA methylation) aberration 
rate (in tumor vs. normal) of two types of modules  
• Top 10% or 20% of genes which highly used (i.e. one gene involved in multiple gene 
modules) as representative of each types of modules 
• Gatekeeper modules 
have a significantly 
lower incident rate of 
somatic gene 
mutation, but a 
notably higher 
incident rate of DNA 
methylation 
aberration 
 
• Supporting the role of 
epigenetic plasticity 
in tumor phenotype 
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Mapping compound action into gene 
networks 
NCI 60 in vitro Drug screen Project 
Connectivity MAP 
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60 cell lines 60 cell lines 
Compound-Gene Correlations 
Activity (A) Targets (T) A•T′ 
Compound/drug A’s there are a measurement of drug activity (A) cross 60 cell line is determined by 
GI 50 (the 50% growth inhibition values) , the concentration of the drug necessary to reduce the 
growth rate of cells by 50% to that of controls.   
  Activity (A)  = -log10(GI50) 
x 
 Activity  
“Sensitivity” = the sensitivity of one particular cell lines to a drug.  
if drug  d1 can effectively inhibit the cell growth of cell line c1, we say “ cell line c1 is sensitive to drug d1”  
 Sensitivity 
Compound in vitro 
screen data 
NCI 60 panel gene 
Expression data 
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22,000 genes 
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Define Perturbation Index (PI) to 
quantify Drug action 
Hypothesis 
– To disrupt/perturb cancer network, the key to success is to 
simultaneously perturbs the corresponding gatekeeper modules with 
the checkpoint modules (for better exploit the gene synergy) 
 
• Hi -- the number of hits by compound c 
• Li -- the active links ( i.e. links in which both source 
node and target node are matched by compound c) 
• N -- the number of gatekeeper modules 
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Benchmarking for pre-clinical drug prioritizing 
• Why test? 
– Assess the potential application for prioritizing compounds for clinical 
trials, based on the information available in pre-clinical stage 
• ‘Standard Agent Database’ 
– Originally created by Boyd [29] and ultimately finalized by the NCI 
– Compounds which have been submitted to the FDA for review as a New 
Drug Application 
– OR compounds that have reached a particular high stage of interest at 
the NCI 
• Successful drug list - FDA approved and routinely used drugs  
• Candidate list - the remainder  
• Test what? 
– Whether we could statistically discriminate between these two 
compound lists using the perturbation index  
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Bootstrapping-based assessment of Perturbation Index 
on discriminating successful drugs from the candidate 
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Rank of drugs and agents in clinical development for lung 
cancer according to their Perturbation Index 
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How to quantify synergistic effect of Drug 
Combination? 
Drug 
A 
Drug Perturbation 
Gene list A 
Drug 
B 
Drug Perturbation 
Gene list B 
Drug 
A 
Drug Perturbation 
Gene list AB 
Drug 
B 
Pool 
Together 
(Union) 
PI 
Analysis 
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The Perturbation Index of  
pair-wise combination of lung cancer agents 
• Combination of Bortezomib-
Gemcitabine supported by phase II 
clinical trial evidence 
–  Notable survival benefits in lung cancer 
patients using a Bortezomib + 
gemcitabine/carboplatin  combination as first-
line treatment (phase II clinical trial reported) 
• Davies, A.M. et al. J Thorac Oncol 4, 87-92 (2009) 
 
• Combination of Bortezomib-
Paclitaxel supported by literatures 
– In an RNA interference (RNAi)-based synthetic 
lethal screen for seeking paclitaxel 
chemosensitizer genes in human NSCLC cell 
line, proteasome is the most enriched gene 
group 
• Whitehurst, A.W. et al. Nature 446, 815-819 (2007) 
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Bortezomib-Gemcitabine Combination 
Bortezomib 
 
add a focused 
perturbation 
on key 
gatekeeper 
modules 
Gemcitabine 
 
baseline 
perturbation 
Gemcitabine 
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Discussion (1):  As preclinical cancer modeling tool 
• Mirroring drug behavior on heterogeneous patients 
population 
• Cost-effectiveness 
• Easy to integrate drug action mechanisms/patterns 
‚For more than a decade, scientists in systems biology have promised 
that real breakthrough in genetic medicine will come when we stop 
mapping individual genes to phenotypes and instead start looking at 
interacting networks. Yet, not much has happened. The field is still 
struggling to define relevant networks and to interpret data in terms 
of those networks. 
  
The paper by Xiong et al adds considerably to the progress of 
network-based genetic medicine. It is highly relevant, original and 
interesting. ‚ 
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Discussion (2) :  novel strategy against cancer 
• Gatekeeper modules as rate-limiting steps in therapeutic treatment 
 Drug metabolism and accessibility 
 Microenvironment 
 immune system modulation  
• Epigenetic plasticity on gatekeeper modules could exploited by 
tumor for attaining resistance to treatment  
• Suggest a novel strategy against cancer 
– Traditional strategy:   dig the history of tumorigenesis 
<etiology, TCGA effort> to find drug target ? 
– Alternative  strategy:  predict future survival strategy of 
tumor under therapeutic interventions 
• Systems biology modeling could provide prediction of the 
tumor survival strategy 
The next generation therapeutic strategy 
Etiology-based strategy Prediction-based strategy 
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Discussion (3) : Traditional Chinese Medicine 
• 君 - King 
• 臣 - Minister 
• 佐 - Assistant 
• 使 - Ambassador 
provide new perspective to understand principle of 
drug combination 
Based on this method, we could 
interrogate different roles of the 
gene modules 
& their cooperation effects 
provide approach for rational design of drug 
combination 
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Case Study II 
 
Dynamic remodeling of  
context-specific miRNAs regulation networks 
facilitate in silico cancer drug screening 
 
Reference 
• Lida Zhu, …, Jianghui Xiong**. Dynamic remodeling of context-specific miRNAs 
regulation networks facilitate in silico cancer drug screening. Proceedings of 2011 IEEE 
International Conference on Systems Biology (ISB). 2011 
• Xionghui Zhou, …, Jianghui Xiong**. Context-Specific miRNA Regulation Network 
Predicts Cancer Prognosis. Proceedings of 2011 IEEE International Conference on Systems 
Biology (ISB). 2011 
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in silico drug screening 
• Virtual drug screening is a computational technique 
used in drug discovery research. 
• In silico is an expression used to mean “performed on 
computer or via computer simulation”. 
• In silico drug screening is thought to have the potential 
to speed the rate of discovery while reducing the need 
for expensive lab work and clinical trials. 
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Drug repositioning 
-- the application of known drugs and compounds to new 
indications 
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 mRNA-CMAP:  
 Data source: human gene mRNA expression.  
 Method: GSEA 
 This project set out to create a reference collection of gene expression 
profiles from cultured human cells treated with bioactive small 
molecules, and can be used to discover connections among small 
molecules sharing a mechanism of action, chemicals and physiological 
process. 
Connectivity MAP (CMAP) 
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The Connectivity Map: Using Gene-Expression Signatures 
to Connect Small Molecules, Genes, and Disease .   
Lamb et al. Science .29 September 2006: 1929-1935 
Connectivity MAP (CMAP) 
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MicroRNAs (miRNAs)  
• MicroRNAs (miRNAs) play a key role in 
the regulation of the transcriptome. 
 
• miRNAs have been identified as a key 
mediator in human disease and drug 
response. 
 
However,  in methodology, 
even if miRNA expression can be precisely detected,  
the information regarding miRNAs action  
on a particular part of the transcriptome is still lacking… 
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We proposed to 
• Reveal the global network of miRNAs 
action on specific part of the 
transcriptome  
 
• Use this network to understand drug 
Mechanism of Action (MOA) 
 
• Demo its application on drug screening 
(drug positioning) 
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Context-specific miRNA activity  
(CoMi activity) 
GO Term  
Gene Set Pool 
CoMi-Probe 
…… 
CoMi-Probe Set Pool 
Non-Target Gene 
Target Gene 
CoMi-Probe 
Down-regulated CoMi-activity 
   miRNAs target genes    
   significantly up-regulated 
Not Changed CoMi-activity 
   miRNAs target genes 
   not significant changed 
 Up-regulated CoMi-activity 
   miRNAs target genes      
   significantly down-regulated 
CoMi-activity 
Calculation 
i. 
ii. 
iii. 
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Previously we demoed its application 
on cancer prognosis prediction 
• Xionghui Zhou, …, Jianghui Xiong**. Context-
Specific miRNA Regulation Network Predicts 
Cancer Prognosis. Proceedings of 2011 IEEE 
International Conference on Systems Biology 
(ISB). 2011 
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Hsa-miR-27a Hsa-miR-183* Hsa-miR-34a 
CoMi activity network (Breast cancer) could 
highlight key onco-miRNAs and tumor supressor 
miRNAs 
known onco-miRNAs (hsa-miR-183*, has-miR-27a) , tumor suppressor miRNAs (hsa-miR-34a) 
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GO: Signal transduction 
GO: Apoptosis GO: Transport 
GO: regulation of apoptosis 
CoMi activity network (Breast cancer) highlighted 
key pathways in cancer 
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CoMi network provide a promising way to understand the 
Mechanism of action of Paclitaxel on breast cancer 
Dys-regulated network in Breast cancer Paclitaxel can counteract the network 
(green lines    red lines) 
• green lines = down-
regulated CoMi 
• red lines= up-regulated 
CoMi 
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Performance benchmarking as drug 
screening (drug repositioning) method 
 
• Standard Agent Database： 
– 17 drugs mapping with CMAP，103 Instances. 
• Breast cancer treatment:  
– Paclitaxel 
– Tamoxifen 
– Mitoxantrone 
– Vinblastine sulfate 
 
– 19 Instances of treatment. 19/103;4/17 
 
• We tests which method could ranked the treatment drugs on 
the top of the drug ranked list. 
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CoMi –based method has the best stability index as 
drug screening system 
(i) CMAP method 
 (ii) mRNA-based method  
(iii) CoMi activity –based method 
 
DSP: Drug screening performance 
  
Level 1: 
     DSP index > 0 
     DSP p-value < 0.05 
Level 2: 
     DSP index > 0 
     DSP p-value < 0.1 
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Comparison between drug list 
CoMi activity-based method vs. CMAP method 
Drug list of CoMi activity-based method Drug list of CMAP method 
Rank Drug KS Score Rank Drug KS Score 
1 mercaptopurine 0.9417 1 decitabine 0.6893 
2 mitoxantrone 0.6214 2 lomustine 0.4587 
3 vinblastine 0.5825 3 tamoxifen 0.4397 
4 daunorubicin 0.5073 4 procarbazine 0.4369 
5 doxorubicin 0.4563 5 chlorambucil 0.4223 
6 lomustine 0.4029 6 mitoxantrone 0.3883 
7 tamoxifen 0.3329 7 paclitaxel 0.3576 
8 paclitaxel 0.2427 8 etoposide 0.2646 
azacitidine -0.2524 daunorubicin -0.3811 
methotrexate -0.2755 tetrandrine -0.4393 
etoposide -0.3107 methotrexate -0.4660 
hycanthone -0.3131 vinblastine -0.4919 
tetrandrine -0.3204 hycanthone -0.4951 
chlorambucil -0.3981 doxorubicin -0.5146 
procarbazine -0.5696 azacitidine -0.5728 
decitabine -0.8835 mercaptopurine -0.9417 
Wrong 
prediction! 
• Our method successfully boost all positive drugs within the top 8 
• Traditional CMAP method made a wrong prediction  
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• CoMi network provide a promising way 
to understand the Mechanism of action 
of drugs 
 
• As a drug screening/drug repositioning 
method, CoMi method strikingly 
outperformed the traditional CMAP 
method 
 
 
Summary for CoMi method 
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What’s next? 
• Network models library is the infrastructure 
of Network pharmacology efforts 
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There are huge innovative opportunities 
on establishing diverse network, we set 
out to compile a comprehensive Network 
models library 
• Diverse types of node 
– Gene 
– Gene modules 
– microRNAs 
– Long non-coding RNAs … 
• Diverse types of edge (interaction) 
– Physical interaction 
– Genetic interaction 
– Co-expression 
– Bayesian … 
• Various metric for target identification 
– Connectivity (hub) 
– Bridging centrality 
– Hierarchy… 
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Network models library? 
• For genetic interaction 
– Different phenotype define different type of networks  
– Different experimental methods 
– Different context (cell lines, tissue source..)  
 
• Not all biologists are computational biologists, we 
need pre-defined network models  
 
• “The library of Network Models” 
– Annotate 
– Benchmark/validate 
– Updating 
– Integrating 
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Inter-organ network 
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“我们所观测到的不是自然本身，而是自然根据
我们探索它的方法的展现” 
——维尔纳·海森堡  (“测不准原理”, 量子力学，1932年诺贝尔物理学奖) 
@   Jianghui Xiong  熊江辉  Laserxiong  AT gmail.com 
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